Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.40 |
| ▸ | CCR5 | P51681 | 8/20 | 0.37 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.35 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20139469 | 0.80 | SLC5A1 (0.51) | MEN1HTTKMT2AALDH1A1SLC5A1 | |
| SCHEMBL20139395 | 0.77 | HTR2A (0.39) | HPGDADRA2AADRA2BADRA2CSLC5A1 | |
| SCHEMBL7812842 | 0.74 | KMT2A (0.62) | MEN1HTTKMT2AMAPK1ALDH1A1 | |
| SCHEMBL7812819 | 0.73 | MAPK1 (0.66) | MEN1HTTKMT2AMAPK1ALDH1A1 | |
| SCHEMBL20139367 | 0.72 | SLC5A2 (0.48) | ALDH1A1HPGDCCR5SLC5A1SLC5A2 | |
| SCHEMBL20139385 | 0.72 | SLC5A1 (0.48) | ALDH1A1SLC5A1SLC5A2CETP | |
| SCHEMBL20139699 | 0.72 | HPGD (0.44) | MEN1HTTKMT2AMAPK1ALDH1A1 | |
| SCHEMBL2187712 | 0.71 | MAPK1 (0.59) | MEN1HTTKMT2AMAPK1ALDH1A1 | |
| SCHEMBL2322279 | 0.69 | HPGD (0.59) | MEN1HTTKMT2AMAPK1ALDH1A1 | |
| SCHEMBL14392489 | 0.69 | HPGD (0.59) | MEN1HTTKMT2AMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-27 | — | — | US | disclosed |
| WO-2018089449-A1 | BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | SLC5A2, SLC5A1, SLC2A2 | MEN1 4069/4885HTT 3262/4885KMT2A 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.